01—Abstract
Summary
Summary of the 8-K filed August 31, 2026. Cited figures are marked; the original filing is the authoritative source.
Exelixis announced that the U.S. Court of Appeals for the Federal Circuit affirmed the District of Delaware's judgment in Exelixis, Inc. v.
MSN Laboratories Private Limited et al. (Appeal No. 25-1236) that U.S. Patent Nos. 11,091,439, 11,091,440 and 11,098,015 are not invalid. The Court of Appeals also dismissed as moot MSN's appeal regarding the validity of U.S. Patent No. 11,298,349, which expires on February 10, 2032, and vacated the portion of the district court's decision addressing that patent.
Based on the appellate opinion, the effective date of any final FDA approval of MSN's ANDA will not be earlier than January 15, 2030, the expiration date of the three upheld patents. The filing states this is subject to further appellate proceedings, applicable regulatory exclusivity, and the outcome of separate litigation over U.S. Patent No. 12,128,039, which expires in February 2032.
Trial in that litigation is currently scheduled to begin in November 2026. The filing is a Form 8-K under Item 8.01 (Other Events) and includes forward-looking statements about the timing of any MSN generic launch in the U.S., pending litigation outcomes, and regulatory exclusivity, which the company notes are subject to the risks described in its Form 10-K and Form 10-Q filings.
02—Key points
Key Highlights
- The Federal Circuit affirmed that U.S. Patent Nos. 11,091,439, 11,091,440 and 11,098,015 are not invalid, upholding the District of Delaware judgment in favor of Exelixis.
- The Court of Appeals dismissed as moot MSN's appeal on U.S. Patent No. 11,298,349 (expires February 10, 2032) and vacated the related portion of the district court's decision.
- Any final FDA approval of MSN's ANDA is not to take effect before January 15, 2030, the expiration date of the three upheld patents, subject to further appeals, regulatory exclusivity and other litigation.
- Separate litigation over U.S. Patent No. 12,128,039 (expires February 2032) remains pending, with trial scheduled to begin in November 2026.
- The filing contains forward-looking statements on the timing of a potential MSN generic launch, pending litigation and regulatory exclusivity, subject to risks described in the company's SEC filings.
03—Questions
Frequently Asked Questions
What did the Federal Circuit decide?
The Federal Circuit affirmed the District of Delaware's judgment that U.S. Patent Nos. 11,091,439, 11,091,440 and 11,098,015 are not invalid. It also dismissed MSN's appeal on U.S. Patent No. 11,298,349 as moot and vacated the portion of the lower court's decision addressing that patent.
When could MSN's generic product receive FDA approval?
The filing states that the effective date of any final FDA approval of MSN's ANDA will not be earlier than January 15, 2030, the expiration date of the three upheld patents. This is subject to further appellate proceedings, applicable regulatory exclusivity, and the outcome of separate litigation over U.S. Patent No. 12,128,039.
What litigation remains open?
The filing identifies separate litigation involving U.S. Patent No. 12,128,039, which expires in February 2032. Trial in that case is currently scheduled to begin in November 2026.
Does the decision affect U.S. Patent No. 11,298,349?
The Court of Appeals dismissed MSN's appeal on the validity of U.S. Patent No. 11,298,349 as moot and vacated the district court's decision on that issue. The filing does not state a separate ruling on the patent's validity.
04—Continue